On Aug. 2, 2021, Vaxart announced that the U.S. Food and Drug Administration had cleared Vaxart’s Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. The Phase II clinical trial with the S-only construct was expected to start in second half of 2021.